Anagen formulation · 5 activesBFor The Ladies, tuned for post-menopausal hair loss

For The Ladies Max

The higher-estriol variant of For The Ladies. Same five actives, but with estriol bumped from 0.02% to 0.1% — designed for post-menopausal users with more pronounced estrogen-decline-driven hair loss.

What's in it

Every active in For The Ladies Max

Each active in this formulation, scored against its own standalone evidence for AGA. Click any active for the full claim-by-claim breakdown.

Active	Grade	Why it's in this formula
Spironolactone0.25% Anti-androgen (topical)	B	Same dose as standard For The Ladies. Topical anti-androgen with supportive RCT data.
Liothyronine (T3)6.5 ng/mL→Anagen induction	C	Same microdose T3.
Estriol0.1% Estrogenic adjunct (higher-dose)	C	5× higher estriol concentration than the standard For The Ladies. The estrogenic axis dominates in post-menopausal pattern hair loss, where systemic estrogen production has dropped sharply. The higher dose is calibrated for this population. The closest published topical-estrogen analog (17α-estradiol 0.025%) has phase IV trial data showing significant hair count improvement; whether estriol at 5× that concentration produces proportionally larger benefit isn't directly studied.
Minoxidil5%→Follicular activator	A	FDA-approved 5% topical minoxidil for female pattern hair loss.
Levocetirizine0.5%→Anti-inflammatory / anti-PGD2	C	PGD2-pathway adjunct.

The case for this stack

Why we paired these actives

Why a higher estriol dose for post-menopausal hair loss

For The Ladies Max exists for a specific subgroup: women whose hair loss is more strongly driven by estrogen decline. Post-menopausal hair loss often presents with thinning patterns that respond preferentially to estrogenic interventions — the systemic estrogen drop after menopause has direct effects on hair follicle anagen duration and miniaturization risk. The formulation is identical to standard For The Ladies in four of its five components. The single change is estriol: bumped from 0.02% to 0.1% — a 5× higher concentration of the estrogenic active. This is the dose calibrated for users whose hair-loss pattern suggests more pronounced estrogenic etiology. The supporting evidence is the same as For The Ladies: topical estrogen has phase IV trial data for female pattern hair loss (17α-estradiol 0.025% in the Ell-Cranell® alpha study), with significant hair count and diameter improvements at 8 months. Whether estriol at 0.1% (a higher concentration of a weaker estrogen) produces commensurately stronger results than the 0.02% standard dose isn't directly tested — but the pharmacologic rationale for a higher dose in post-menopausal patients is strong.

Cited literature

Kim JH, Lee SY, Lee HJ, Yoon NY, Lee WS (2012). The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study. Ann Dermatol PMID 22879713
Choe SJ, Lee S, Choi J, Lee WS (2017). Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation. Ann Dermatol PMID 28566902
Hassan GFR, Elsaftawy RE, Mady OY, Gheida SF (2025). Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment of Female Pattern Hair Loss: A Comparative, Clinical, and Trichoscopic Study. Int J Trichology PMID 40654550

What's been studied

The studies behind the combination

Same evidentiary picture as For The Ladies — per-component and per-pairing data, no RCT of the exact five-active formulation. The higher estriol concentration is the formulation-specific variable that isn't directly studied.

Kim 2012 — Topical 17α-estradiol phase IV (closest analog to estriol)

Ann Dermatol · PMID 22879713

OPEN-LABEL

Design

Open-label phase IV

Duration

8 months

Topical 17α-estradiol 0.025% produced statistically significant increases in hair count and diameter in women with female pattern hair loss. Most directly cited topical-estrogen evidence for FPHL. Anagen's For The Ladies Max uses estriol at 0.1% — different molecule, higher concentration, not directly compared.

Choe 2017 — Topical estrogen + minoxidil combination

Ann Dermatol · PMID 28566902

OBSERVATIONAL

Design

Retrospective

—

Duration

6 months

Combination 17α-estradiol 0.025% + topical minoxidil 3% increased total hair count and hair caliber in FPHL. Supports the estrogen + minoxidil combination strategy.

Hassan 2025 — Topical spironolactone vs minoxidil in FPHL

Int J Trichology · PMID 40654550

RCT

Design

Comparative RCT

Duration

6 months

Topical 1% spironolactone produced clinical improvement in female pattern hair loss comparable to topical 5% minoxidil. Anagen uses 0.25%.

Honest limits

What the science doesn't yet answer

No RCT has tested estriol at 0.1% specifically. The dose is a pharmacologic calibration for post-menopausal users; whether it outperforms For The Ladies' 0.02% in this population is reasonable to expect but not directly studied.
Estriol vs 17α-estradiol head-to-head for topical hair growth is unstudied — the choice of estriol is anchored in safety profile (estriol is a weaker estrogen with lower systemic absorption concern) rather than direct head-to-head data.
Whether the higher estriol dose produces clinically meaningful systemic exposure in post-menopausal users isn't directly characterized at this concentration.
Same five-active-combination caveats as For The Ladies — no RCT of the exact formulation, the case is mechanism + per-component evidence.

Bottom line

Our verdict on For The Ladies Max

Post-menopausal calibration

For The Ladies Max is For The Ladies tuned for the post-menopausal patient. The 5× higher estriol concentration is the central design variable — calibrated for users whose hair loss is more strongly driven by estrogen decline. The evidentiary footing is the same as For The Ladies (Grade B): supportive per-component data, no RCT of the exact formulation. The case for the higher estriol dose is pharmacologic rather than directly tested — the published topical-estrogen evidence uses different molecules and lower doses. Anagen's choice of estriol (a weaker estrogen than 17α-estradiol) at a higher concentration is a deliberate safety-side calibration. For pre-menopausal or peri-menopausal users where androgen-driven mechanisms still dominate, For The Ladies (lower estriol) is the more conservative starting point. For post-menopausal users with estrogen-driven thinning patterns, For The Ladies Max is the calibrated escalation.

Post-menopausal calibration of the For The Ladies stack. Same evidentiary footing as the standard formulation; the 5× higher estriol concentration is the deliberate variable.

The product